AFC
NBIX icon

Ares Financial Consulting’s Neurocrine Biosciences NBIX Stock Holding History

Ares Financial Consulting’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89K Buy
29
+5
+21% +$742 ﹤0.01% 713
2026
Q1 		$3.18K Hold
24
– – ﹤0.01% 771
2025
Q4 		$3.4K Buy
+24
New +$3.48K ﹤0.01% 556

Other funds holding NBIX

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Ares Financial Consulting's NBIX Position: Q2 2026 in Review

Ares Financial Consulting increased its Neurocrine Biosciences (NBIX) stake by 21% in Q2 2026, buying an estimated $742 and bringing the position to 29 shares worth $4.89K. The position accounts for ﹤0.01% of the portfolio, ranked #713.

Ares Financial Consulting first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 352 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Ares Financial Consulting held 29 shares of Neurocrine Biosciences worth $4.89K as of Q2 2026.
  • Ares Financial Consulting bought 5 Neurocrine Biosciences shares in Q2 2026, an estimated $742.
  • Neurocrine Biosciences made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #713 holding.
  • Ares Financial Consulting first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 352 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.